Mussallem Michael A's Form 4 filing
Edwards Lifesciences Corp (EW) · filed Oct 1, 2021
- Accession no.
- 0001225208-21-012665
- Filed
- Oct 1, 2021
- Trade date
- Oct 1, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.64M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mussallem Michael ACIK 0001204551 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2021 | Common Stock | MOption exerciseAcquired | +45,050 | $21.76 | +$980,288 | 233,051.82 | Direct | |
| Oct 1, 2021 | Common Stock | SSaleDisposed | −300 | $113.10F2 | −$33,930 | 232,751.82 | Direct | |
| Oct 1, 2021 | Common Stock | GGiftDisposed | −12,500 | $0.00 | $0 | 220,251.82 | Direct | |
| Oct 1, 2021 | Common Stock | SSaleDisposed | −14,132 | $112.17F3 | −$1,585,186.44 | 206,119.82 | Direct | |
| Oct 1, 2021 | Common Stock | SSaleDisposed | −18,118 | $111.34F4 | −$2,017,258.12 | 188,001.82 | Direct | |
| Oct 1, 2021 | Common Stock | GGiftAcquired | +12,500 | $0.00 | $0 | 3,210,287 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2021 | Common Stock | MOption exerciseDisposed | −45,050 | $0.00 | $0 | 315,350 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $112.9700 to $113.3250. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $111.6600 to $112.6200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $110.6400 to $111.6400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.